3-ethyl-7-methoxy-1-propyl-1H-pyrimido[5,4-c]quinoline-2,4-dione | 1174226-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 3-ethyl-7-methoxy-1-propyl-1H-pyrimido[5,4-c]quinoline-2,4-dione
• 英文别名: 3-ethyl-7-methoxy-1-propylpyrimido[5,4-c]quinoline-2,4-dione
• CAS: 1174226-34-6
• 化学式: C₁₇H₁₉N₃O₃
• 分子量: 313.356
• InChiKey: UUMJILIRWRRMQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  62.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  8-methoxy-4-propylamino-quinoline-3-carboxylic acid ethylamide 、 氯甲酸甲酯 在 sodium hydride 、 水 作用下， 反应 24.5h， 生成 3-ethyl-7-methoxy-1-propyl-1H-pyrimido[5,4-c]quinoline-2,4-dione
  参考文献：
  名称：

  [EN] TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-a SYNTHESIS AND AS PDE4 INHIBITORS
  [FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA SYNTHÈSE DE TNF-? ET EN TANT QU'INHIBITEURS DE PDE4

  摘要：

  本发明涉及化合物的化学式（I），如本文所定义，药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿关节炎。

  公开号：

  WO2009094528A1

文献信息

• Tricyclic Compounds As Modulators of TNF-alpha Synthesis
  申请人：Mjalli Adnan M. M.

  公开号：US20100190808A1

  公开（公告）日：2010-07-29

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及公式(I)所定义的化合物、药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿关节炎。
• Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20110160234A1

  公开（公告）日：2011-06-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化学式（I）所定义的化合物，制药组合物以及在治疗由TNF-α或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。
• Tricyclic compounds as modulators of TNF-α synthesis
  申请人：High Point Pharmaceuticals, LLC

  公开号：US07964608B2

  公开（公告）日：2011-06-21

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及式（I）所定义的化合物、制药组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。
• Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
  申请人：High Point Pharmaceuticals, LLC

  公开号：US08329715B2

  公开（公告）日：2012-12-11

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化学式（I）所定义的化合物、制药组合物以及在治疗由TNF-α或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿性关节炎。
• TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
  申请人：vTv Therapeutics LLC

  公开号：US20150374700A1

  公开（公告）日：2015-12-31

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及公式（I）所定义的化合物、制药组合物及其在治疗由TNF-α或PDE4介导的疾病或症状方面的使用方法，包括但不限于类风湿性关节炎。